

1 **Triple-targeting nanosystems with synergistic effects on iron Trojan**  
2 **horse, fluoroquinolone antibiotics, and photodynamic therapy**  
3 **specifically kill intracellular MRSA**

4 Kuiyu Meng<sup>a,b</sup>, Liwen Yuan<sup>c</sup>, Lulu Feng<sup>a</sup>, Yaoyao Zhang<sup>b</sup>, Hao Wu<sup>b</sup>, Jie Zhang<sup>b</sup>,  
5 Mubbashar Abbas<sup>a</sup>, Wei Qu<sup>c</sup>, Dongmei Chen<sup>c</sup>, Shuyu Xie<sup>a,b,c,d\*</sup>

6 <sup>a</sup>National Key Laboratory of Agricultural Microbiology, Huazhong Agricultural  
7 University, Wuhan, Hubei 430070, China

8 <sup>b</sup>Hubei hongshan Laboratory, Wuhan, Hubei 430070, China

9 <sup>c</sup>National Reference Laboratory of Veterinary Drug Residues (HZAU), Wuhan,  
10 Hubei 430070, China

11 <sup>d</sup>Key Laboratory of Prevention & Control for African Swine Fever and Other  
12 Major Pig Diseases, Ministry of Agriculture and Rural Affairs, Wuhan, Hubei  
13 430070, China

14 \*Corresponding author:

15 Professor Shuyu Xie, E-mail: [Xieshuyu@mail.hzau.edu.cn](mailto:Xieshuyu@mail.hzau.edu.cn), Tel:  
16 +86-27-87287323-8110, Fax: +86-27-87672232

17

18

19

20

21

22

## 23 **Materials and Methods**

### 24 **Synthesis of GaPR**

25 The protoporphyrin IX dimethyl ester (0.5 g) was dissolved in 30 mL of  
26 2,6-lutidine and then added dropwise to 10 mL of 2,6-lutidine containing  
27 gallium chloride (4.93 g) under nitrogen addition. The mixture was reacted for  
28 6 h at 150 °C. After cooling, 500 mL of concentrated salt solution was added  
29 and the pH was adjusted to 4 with citric acid. The purple sediment was  
30 collected, washed with deionized water (3 x 100 mL) and identified by UV/vis.

### 31 **Synthesis of HA-TK-NH<sub>2</sub>**

32 500 mg HA was dispersed in 500 mL pH 7 deionized water contained 310 mg  
33 1-(3-Dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 115 mg  
34 N-Hydroxysuccinimide. The mixture was stirred at 300 rpm for 4 h, and 194 mg  
35 HA-TK-NH<sub>2</sub> was added for continuous stirring for 24 h. The product was  
36 obtained by dialysis in deionized aqueous solution.

### 37 **Size and zeta potential determination**

38 The DLS and zeta potential were conducted by a Zetasizer Nano ZS ZEN3600  
39 analyzer (Malvern Instrument, Britain). The zeta potential was obtained by  
40 measuring the electrophoretic movement of charged nanosystems under an  
41 applied electric field.

### 42 **TEM observation**

43 TEM images of different nanosystems were taken on a JEOL JEM-2100F  
44 (Japan) at an acceleration voltage of 200 keV by dropping the samples onto a

45 carbon-coated copper grid. The Image-Pro Plus image analysis software was  
46 used to measure the diameter of nanoparticles.

#### 47 **SEM observation**

48 The nanosystems were adhered to the conductive adhesive and sprayed with  
49 gold with Quorum SC7620 for 45s. Then, the morphology was observed with  
50 TESCAN MIRA LMS (Czech) of scanning electron microscope.

#### 51 **Determination of $^1\text{O}_2$**

52 10  $\mu\text{l}$  of the 5  $\mu\text{M}$  SOSG fluorescent probe methanol solution was added to 5  $\mu\text{l}$   
53 of Lev-PCN-224, Lev-GaPR-PCN and HA-Lev-GaPR-PCN suspension and  
54 then mixed uniformly with 85  $\mu\text{l}$  of water. Under irradiation with a laser (660 nm)  
55 at different time points, the fluorescence intensity was measured using a  
56 multilabel microplate detection system (PerkinElmer Ltd., MA, USA) at an  
57 excitation/emission (Ex/Em) of 490/520 (SOSG). After successful infection of  
58 RAW264.7 cells with MRSA for 4 h, the cells were treated separately with 8  
59  $\mu\text{g}/\text{mL}$  of different nanosystems for 0.5-2 h. After 30 min of irradiation, the  
60 culture medium was washed off, SOSG was added and incubated at 37  $^\circ\text{C}$  for  
61 30 min. The intracellular fluorescence was analyzed by flow cytometry (ex: 490  
62 nm, em: 520 nm).

#### 63 ***In vitro* cytotoxicity**

64 Cells ( $5 \times 10^3$  cells/well) were cultured in sterile 96-well plates for 24 h and  
65 treated with different concentrations of HA-Lev-GaPR-PCN (1.0, 2.0, 5.0, 10.0  
66 and 20.0  $\mu\text{g}/\text{mL}$ ) for 4 h. They were then irradiated at 660 nm for 10, 10+10

67 (with a break of 30 min), 10+10+10 (with two breaks of 30 min), 20 and 30 min,  
68 respectively. The cells were then incubated for 24 hours after replacement with  
69 fresh culture medium before the cytotoxicity of the cells was checked using the  
70 MTT assay according to the manufacturer's protocol.

#### 71 **Bio-layer interferometry binding (BLI) kinetics assay**

72 BLI was analyzed with the Fortebio red96e (PALL, USA) at an oscillation  
73 speed of 1000 rpm and a plate temperature of 30 °C. The biotinylation ligand  
74 protein was prepared according to the manufacturer's instructions using the kit  
75 (ARL0020S, Frdbio). Before testing the target analyte, the streptavidin light  
76 guide probe was placed in PBS for 10 min to load the biotinylation ligand (100  
77 µg/mL) for 10 min. Then the probe was bound to different concentrations (10, 5,  
78 2.5, 1, and 0 µg/mL) of analytes for 90 s to determine binding kinetics, followed  
79 by dissociation in PBS for 150 s.

#### 80 **Live/Dead cell staining assay**

81 After successful infection of RAW264.7 cells with MRSA for 4 h, the cells were  
82 treated separately with 8 µg/mL Lev, Lev-PCN-224 and Lev-GaPR-PCN for 20  
83 h. Then, the incubated cells were stained with a live/dead staining solution  
84 (Invitrogen, USA) (5 µM SYTO 9, 30 µM PI) for 20 min. Subsequently, the  
85 intracellular live/dead MRSA was observed using CLSM (Nikon, N-STORM,  
86 Japan).

#### 87 **qRT-PCR analysis**

88 The MRSA at the concentration of  $10^8$  CFU was grown in 1640 and TSA  
89 medium under 220 rpm at 37 ° C for 4 h. The bacteria suspension was  
90 centrifuged at 12000 r/mim for 5 min, and then 100  $\mu$ L of 2.5  $\mu$ g/ml lysostaphin  
91 and 0.25  $\mu$ g/ml lysozyme were added, respectively. The cell suspension was  
92 incubated at 37 ° C for 15 min and then extracted by RNeasy mini kit (Qiagen)  
93 according to the manufacturer's instructions. ImProm II cDNA Synthesis Kit  
94 (Promega) was used for RNA (50 ng/ $\mu$ L) generating cDNA. The referred  
95 primer sequences are shown in Table S1. The cDNA was analyzed with  
96 LightCycler 480 II real-time PCR instrument and SYBR reagent (Bio-Rad,  
97 USA).

#### 98 **Antibacterial activity determination**

99 Extracellular MIC: Clinical MRSA isolates (B1-1, stored in the National  
100 Veterinary Drug Residues Reference Laboratory of Huazhong Agricultural  
101 University) were recovered and passaged in LB broth medium. MRSA at a  
102 level of  $2 \times 10^5$  CFU/mL was added to 96-well dishes. Different doses of double  
103 dilution of Lev, Lev-PCN-224, Lev-GaPR-PCN and HA-Lev-GaPR-PCN were  
104 added to the 96-well dish respectively. The 96-well dish was then irradiated  
105 with a 660 nm laser at a power of 100 mW/cm<sup>2</sup> for 10 min. After a break of 30  
106 min, it was irradiated again for 10 min. The 96-well dish was then incubated at  
107 37 °C for 24 h. The extracellular MIC was determined using the lowest dose  
108 that completely inhibits the proliferation of MRSA by determining the OD value  
109 at 600 nm.


110 Intracellular MIC: RAW 264.7 cells were inoculated at a density of  
111 approximately  $10^4$  cells per well from 96-well culture plates and then infected  
112 with approximately  $10^5$  MRSA per well. After the 2-h infection, 200  $\mu\text{g}/\text{mL}$   
113 gentamycin was added to the DMEM culture medium to completely eliminate  
114 the extracellular MRSA. Different doses of double dilutions of Lev,  
115 Lev-PCN-224, Lev-GaPR-PCN and HA-Lev-GaPR-PCN (calculated as Lev)  
116 were each incubated for 24 h to determine the intracellular MIC. PBS was used  
117 as a control. After a 4-h addition of Lev and nanosystems, all cells were  
118 irradiated twice for 10 min with a 660-nm laser at a power of  $100 \text{ mW}/\text{cm}^2$   
119 (30-min break between the two irradiations). After 18 h of cultivation, the  
120 extracellular MRSA were removed by washing three times with PBS, and the  
121 intracellular bacteria were determined by the OD value at 600 nm of the cell  
122 lysates. The intracellular MIC was determined by the lowest dose that  
123 completely inhibited the proliferation of intracellular MRSA by determining the  
124 OD value.

### 125 **Safety study**

126 To evaluate the safety of mice, healthy Balb/C mice were injected with  
127 HA-Lev-GaPR-PCN via a tail vein for 14 d at a daily dose of 36 mg/kg  
128 (calculated as Lev). At the end of the experiment, the hematological and  
129 biochemical parameters were analyzed. Heart, liver, spleen, lung and kidney  
130 were weighed after necropsy to obtain organ coefficients. The heart, liver,  
131 spleen, lung and kidney were then removed, fixed with 4 % formaldehyde and


132 dehydrated with ethanol. After kerosene embedding, the tissues were sliced  
133 for subsequent staining and analysis.

## 134 Result



135

136 **Figure S1. Design and screening of targeting nutritional competitive**  
137 **antibiotics (trojan horse). A) UV-vis DRS spectra of FePR, GaPR, MnPR,**  
138 **ZnPR, and protoporphyrin. B) The binding efficiency of of TCP and GaPR**  
139 **with Hpg and CD163 determined by BLI. C) UV-vis DRS spectra of Lev,**  
140 **GaPR-PCN, Lev-GaPR-PCN, and HA-Lev-GaPR-PCN.**



141

142 **Figure S2. Characterization and programmed release of different**

143 **nanosystems. A)** DLS size of GaPR-PCN added 25-200 mg GAPR. **B)**

144 Cellular uptake of various HA-Lev-GaPR-PCN by sterile RAW 264.7 cells.

145 and HA-Lev-GaPR-PCN **C)** DLS size of HA-Lev-GaPR-PCN added 10-50 mg


146 HA-TK-NH<sub>2</sub>. **D)** DLS of Lev-GaPR-PCN in PBS, sterile cells, and MRSA

147 infected cells. **E)** DLS and zeta potential of HA-Lev-GaPR-PCN in PBS, water,

148 and DMEM (10% FBS) for 14 d. **F)** XRD pattern of HA-Lev-GaPR-PCN in



149 DMEM (10% FBS) for 14 d. (graph changed to arbitrary unit). **G)** Absorbance  
150 value of singlet oxygen produced by Lev-PCN-224, Lev-GaPR-PCN and  
151 HA-Lev-GaPR-PCN incubating with pH7.4 PBS. **H)** Fluorescence intensity of  
152 intracellular singlet oxygen when Lev-PCN-224, Lev-GaPR-PCN and  
153 HA-Lev-GaPR-PCN incubating with sterile and infected RAW 264.7 cells. **I)**  
154 TEM images of of HA-Lev-GaPR-PCN after incubating with MRSA infected  
155 cells for different time points. **J)** Flowcytometry images of APC-A700  
156 fluorescence counts on MRSA after co-incubating with PCN-224 and  
157 GaPR-PCN for 15 min, 30 min, and 60 min.



158

159 **Figure S3. Targeting performance and mechanism of nanosystems to**

160 **infected cells and intracellular MRSA. A) CLSM images of**

161 **HA-Lev-GaPR-PCN inside RAW 264.7 after incubating for 4h. B) Continuous**

162 confocal fluorescence microscope images for transporting of PCN-224 and  
 163 GaPR-PCN into sterile RAW 264.7 for 5-25min. Scale bars, 10  $\mu$ m. **C)** The  
 164 binding efficiency of GaPR and GaPR-PCN with Hpx, LRP1, as well as their  
 165 combined complexes with LRP1 determined by BLI sensorgrams. **D)** The  
 166 binding efficiency of TCPP, GaPR and GaPR-PCN with Hpx, LRP1, and Hpg,  
 167 as well as their combined complexes with CD163 determined by BLI  
 168 sensorgrams. **E)** Continuous confocal fluorescence microscope images of  
 169 HA-GaPR-PCN transport into MRSA infected RAW 264.7 cells during 125-145  
 170 min. Scale bars, 5  $\mu$ m. **F)** Intracellular co-localization of GaPR-PCN with  
 171 trans-Golgi network. Scale bars, 10  $\mu$ m. **G-H)** Cellular uptake of  
 172 Lev-GaPR-PCN by sterile and MRSA-infected RAW 264.7 cells, when Hpx,  
 173 Hpg, and heme were added. Added heme (+), Do not added heme (-). **I)** RAW  
 174 264.7 viability after treatment with different concentrations of  
 175 HA-Lev-GaPR-PCN (1.0, 2.0, 5.0, 10.0, and 20.0  $\mu$ g/mL). **J)** RAW 264.7  
 176 viability after treatment with HA-Lev-GaPR-PCN (10  $\mu$ g/mL), under irradiating  
 177 at 660 nm for 10, 20, and 30 min. **K)** RAW 264.7 viability after treatment with  
 178 HA-Lev-GaPR-PCN (10  $\mu$ g/mL), under irradiating for 10, 10+10 (a break of 30  
 179 min), and 10+10+10 (two break of 30 min) at 660 nm.

180

181 **Table S1. Primer sequences for *isd b* and *Isd h***

Gene	Forward Sequence (5'to3')	Reverse Sequence (5'to3')
<i>isd b</i>	GTCATCACTAGGCGTTGCATCTG	GCTTCTGTATTTGTACCACCTGTTTCT

*Isdh* CCCGGATCCGAACATCTGCCGAGTGATATTC

CGGGTCGACCAGTAAGATTATTTCAATTAG

---